Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Does Your Labmate Have the Hands? | Main | Up There, and Down Here »

February 1, 2005

Merck Takes Another One

Email This Entry

Posted by Derek

A lot of people at Merck must be wondering just exactly what they're being paid back for. If you'd sat down a couple of years ago and tried to come up with a doomsday timeline for Merck, you couldn't have done much better than what's actually happened. The latest is Friday's ruling (PDF) that Merck's patent for a weekly dosing formulation of their osteoporosis drug Fosamax is invalid. That's their second-biggest selling drug - the biggest, Zocor, is coming off patent next year, don't you know.

Teva, a generic powerhouse, already has an application in to sell Fosamax (alendronate) in 2008, when the original chemical matter patent expires. But the biggest-selling form of the drug is the weekly dose, and Merck had (so they thought) wrapped up patent protection on that one until 2018. They'd won a round in the District Court in 2003, which found that Teva's application infringed on the Merck formulation patent. But Teva appealed, and the Court of Appeals for the Federal Circuit, to Merck's dismay, reversed the District Court ruling.

That doesn't leave Merck too much room, as I understand it. The Supreme Court doesn't take many patent cases - the last one, I think, was the Festo appeal, and that dealt with more fundamental questions of patent law. This, unfortunately for Merck, just looks like another patent fight, and as such I'd be surprised if the Supreme Court agrees to hear it.

One of the grounds for reversal is an obviousness argument against Merck's patent, based on a 1996 article in a trade publication on the desirability of a weekly dose of alendronate. The other reversal argument comes down to the interpretation of a single word in the original patent claims. Merck claimed a method for treating osteoporosis by administering "about 70 mg" of the compound once weekly, and a method for preventing it by administering "about 35 mg" of the compound weekly. Based on other language in the patent, the District Court believed that this "about" language was an attempt to take into account the different salt forms and formulations of alendronic acid, in order to deliver the exact 35 or 70 mg of sodium alendronate. Teva's application was for 35 and 70 mg dosages, and they were held to infringe.

The CAFC, noting that Merck had acted "as its own lexicographer", pointed out that this would mean that "about 35 mg" now was being held to mean the same thing as "exactly 35 mg.", Noting the weirdness of this, they sharply yanked the definition back to the more commonly accepted one. Teva is now in the clear, and Merck (who probably hoped to throw the largest shadow they could with that adjective) finds themselves in trouble.

There's a testy dissent to the ruling (also in that PDF file above), which the majority opinion describes as ". . .pursuing a philosophical argument as to the deference which should be given to the trial court. Claim construction being a legal matter it is reviewed de novo and this is still the law notwithstanding the desire of some members of this court to consider creating an exception to that rule." Perhaps Howard Bashman has some background on this intra-judicial elbow-throwing. The Patent Law Blog has some comments, too, along with a more technical discussion of the case than I've given here.

Comments (0) + TrackBacks (0) | Category: Patents and IP


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
What If?
Novartis Impresses Where Others Have Failed
Exelixis Against the Wall
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds